90%Confidence
0Views
FDASource
2026-03-05Date
Summary
Third testosterone product recall for Asteria Health confirms widespread contamination issues in their manufacturing processes. This could lead to complete facility shutdown and significant financial liabilities.
Actionable: Consider short positions in companies dependent on Asteria Health's compounding services or similar business models.
AI Confidence: 90%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 25.0 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-1025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now